J&J will ad­vance pso­ri­a­sis drug li­censed from Pro­tag­o­nist af­ter fuller Phase IIb read­out

John­son & John­son’s oral IL-23 that it li­censed from Pro­tag­o­nist Ther­a­peu­tics will move in­to a Phase III tri­al, the health­care gi­ant said, af­ter ad­di­tion­al da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER